Eli Lilly Makes Bold $1 Billion Move to Combat Opioid Crisis with SiteOne Acquisition
On May 28, 2025, Eli Lilly announced its acquisition of SiteOne Therapeutics, a privately held biopharmaceutical company, in a deal valued at up to $1 billion. This strategic move grants Eli Lilly access to STC-004, SiteOne’s experimental non-opioid pain treatment targeting Nav1.8 channels involved in pain signal transmission.
The acquisition aligns with Eli Lilly’s broader strategy to diversify its pain management portfolio beyond traditional opioids. STC-004 represents a novel approach, aiming to provide effective pain relief without the addiction risks associated with opioid therapies. This move positions Eli Lilly to further expand its footprint in the non-opioid pain relief market, addressing a significant unmet need in pain management.
You May Interested In
2026-07-21
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
NHU and Sinopec Advance Liquid Methionine Project
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Lilly’s Mounjaro Enters China’s State Insurance System
Recommend Reading
-
March Acetic Acid Market Strongly Rises in China
-
MTBE Market Trend in China Shows Weak Consolidation
-
On March 9, the Isopropyl Alcohol Market in China Experienced a Significant Price Increase
-
China's phenol market trended upward in March, may remain high in April
-
FDA Color Policy Uncertainty Opens a New Chapter for Food Ingredient Reform